It will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.
Acetazolamide is a potent carbonic anhydrase inhibitor, effective in the control of fluid secretion (e.g. some types of glaucoma), treatment of certain convulsive disorders (e. g. epilepsy) and promotion of diuresis in instances of abnormal fluid retention (e.g. cardiac edema).
The group now has 262 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)